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Abstract
Background: Plasmodium falciparum in a subset of patients can lead to cerebral malaria (CM), a
major contributor to malaria-associated mortality. Despite treatment, CM mortality can be as high
as 30%, while 10% of survivors of the disease may experience short- and long-term neurological
complications. The pathogenesis of CM is mediated by alterations in cytokine and chemokine
homeostasis, inflammation as well as vascular injury and repair processes although their roles are
not fully understood. The hypothesis for this study is that CM-induced changes in inflammatory,
apoptotic and angiogenic factors mediate severity of CM and that their identification will enable
development of new prognostic markers and adjunctive therapies for preventing CM mortalities.
Methods: Plasma samples (133) were obtained from healthy controls (HC, 25), mild malaria (MM,
48), cerebral malaria survivors (CMS, 48), and cerebral malaria non-survivors (CMNS, 12) at
admission to the hospital in Jabalpur, India. Plasma levels of 30 biomarkers ((IL-1β, IL-1ra, IL-2, IL-
4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, Eotaxin, FGF basic protein, G-CSF,
GM-CSF, IFN-γ, IP-10, MCP-1 (MCAF), MIP-1α, MIP-1β, RANTES, TNF-α, Fas-ligand (Fas-L),
soluble Fas (sFas), soluble TNF receptor 1 (sTNF-R1) and soluble TNF receptor 2 (sTNFR-2),
PDGF bb and VEGF)) were simultaneously measured in an initial subset of ten samples from each
group. Only those biomarkers which showed significant differences in the pilot analysis were
chosen for testing on all remaining samples. The results were then compared between the four
groups to determine their role in CM severity.
Results: IP-10, sTNF-R2 and sFas were independently associated with increased risk of CM
associated mortality. CMNS patients had a significantly lower level of the neuroprotective factor
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VEGF when compared to other groups (P < 0.0045). The ratios of VEGF to IP-10, sTNF-R2, and
sFas distinguished CM survivors from non survivors (P < 0.0001).
Conclusion: The results suggest that plasma levels of IP-10, sTNF-R2 and sFas may be potential
biomarkers of CM severity and mortality. VEGF was found to be protective against CM associated
mortality and may be considered for adjunctive therapy to improve the treatment outcome in CM
patients.
Background
Plasmodium falciparum in a subset of patients can lead to a
diffuse encephalopathy known as cerebral malaria (CM),
a major contributor to malaria-associated mortality [1].
Despite treatment, mortality in CM can be as high as 30%
while 10% of survivors of the disease may experience
short- and long-term neurological complications [2]. Plas-
modium falciparum infection and CM have re-emerged in
India, causing considerable morbidity and mortality [3].
Fatal CM is a multi-factorial neurological syndrome
involving reversible vascular occlusion in the presence of
sequestered parasitized erythrocytes (pRBCs) [4], leuko-
cytes [4,5], inflammation [6], apoptosis [6-9], platelets
[10] and angiogenic failures [11]. Although sequestration
of parasites may occur in any vascular bed, the phenome-
non of mechanical obstruction within the brain appears
to be the result of the adherence of pRBCs to other pRBCs,
RBCs, and the endothelium [5,12,13]. Parasite sequestra-
tion alone cannot account for fatal CM pathogenesis as
there is evidence that survivors of the disease have the
same degree of sequestration during comas as those suc-
cumbing to disease [14]. It is evident that a combination
of parasite and host immune factors play an important
role in the pathogenesis of CM [15].
Clinical studies and murine models support a role for pro-
inflammatory (Th1) and anti-inflammatory (Th2)
cytokines and chemokines in the pathogenesis of CM
[16,17]. Although pro-inflammatory cytokines play a
dominant role in parasite destruction and conferring pro-
tection [18], they are also associated with CM pathogene-
sis. Increased plasma levels of TNF-α up regulates the
expression of adhesion molecules, thereby exacerbating
parasite sequestration [19], and correlate with severe dis-
ease [20]. Plasma levels of soluble TNF receptor 1 (sTNF-
R1) and 2 (sTNF-R2), which act as binding proteins for
TNF-α, have been shown to increase in Malawian children
[21] and in post-mortem CSF and serum in Ghanaian CM
non-survivors [22] when compared with levels in conva-
lescent children and in healthy controls. Severe malaria
has also been associated with increased production of
IFN-γ and IL-1β [4] and decreased production of anti-
inflammatory cytokines, notably IL-10 and TGF-β [23].
Chemokines of the C-C or β subfamily, including macro-
phage inflammatory proteins 1 (MIP-1α), MIP-1β, and
Regulated on Activation Normal T cell Expressed and
Secreted (RANTES/CCL5) modulate many infectious and
inflammatory diseases, including malaria. Animal and
post-mortem human studies indicate that expression of
RANTES/CCL5, a chemo-attractant for T cells and mono-
cytes, and its corresponding receptors CCR3 and CCR5 are
elevated in brain tissues of C57BL/6 mice infected with
Plasmodium berghei ANKA and in post-mortem tissues of
CM patients [24,25]. Although recent observations in
Uganda have shown a significant reduction in RANTES in
peripheral blood of severe malaria patients (SM) [26],
MIP-1α and MIP-1β serum levels were elevated [27].
Interferon inducible protein 10 (IP-10), a member of the
CXC or α subfamily, is induced in response to IFN-γ,
which attracts activated Th1 cells [28]. IP-10 levels are ele-
vated in cultured intervillous blood mononuclear cells
isolated from placenta's infected with malaria [29,30],
and in post-mortem CSF and sera in non survivors of CM
[22].
Angiogenic factors, long implicated in ischaemia (stroke)
prognoses [31], may also be involved in CM-induced
petechial haemorrhages and CM-associated brain
endothelium/blood brain barrier (BBB) dysfunction [32].
Vascular endothelial growth factor (VEGF) stimulates
endothelial cell growth, migration, and enhances vascular
permeability. In a post-mortem immunohistological eval-
uation of CM patients, VEGF levels (VEGF+ astrocytes)
were higher in CM patients compared with controls [11].
Platelets, which accumulate with pRBCs in the brain
microvasculature in CM patients, are also implicated in
CM pathology [10,33]. Platelet derived growth factor
(PDGF) stimulates vascular growth and induces regenera-
tion of damaged axons and neuronal growth after
ischemia [31]. PDGFbb levels were lower than that of con-
trols in post-mortem CSF and sera in non-survivors of CM
and were predictive of CM associated mortality [22].
The goal of this study was to test the hypothesis that CM-
induced changes in inflammatory, apoptotic and ang-
iogenic factors mediate severity of CM in India. By evalu-
ating these factors simultaneously using high throughput
multiplex immunoassay techniques, characterization of
these factors is accelerated and identification of new tar-Malaria Journal 2008, 7:83 http://www.malariajournal.com/content/7/1/83
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gets of adjunctive therapies for preventing CM mortalities
is enabled. A prospective study was conducted in Jabalpur,
India to assess the levels of peripheral blood pro-inflam-
matory, apoptotic and angiogenic factors associated with
CM in healthy controls (HC), mild malaria (MM)
patients, CM survivors (CMS), and CM non-survivors
(CMNS). The levels of immunologically-relevant media-
tors of malaria were evaluated to determine their role in
the progression of CM immunopathology in India. The
findings suggest critical roles of IP-10, apoptotic factors
and angiogenic factors in CM-associated mortality.
Methods
Study site
The study was conducted in the Jabalpur province, Mad-
hya Pradesh, India, which is a malaria-endemic region
that accounts for 23% of all malaria cases in the state [34].
The study was carried out at two sites: Nethaji Subash
Chandra Bose (NSCB) Hospital (a regional referral hospi-
tal) in Jabalpur and Civil Hospital (a primary hospital) in
Maihar, Satna District. Both Plasmodium vivax and P. falci-
parum are prevalent in this area, and P. falciparum trans-
mission occurs primarily during the monsoon and post-
monsoon seasons (July – January). Previous studies
revealed that malaria is present in all age groups, with the
highest prevalence occurring in children between 8–14
years of age [35].
Study subjects
Patient recruitment was initiated in October 2004 and
ended in December 2006. All subjects were enrolled after
obtaining informed consent from patients and guardians
of patients with unarousable coma. Informed consent and
human subject research guidelines of the National Insti-
tutes of Health (NIH, USA), and the ethical committees of
the Morehouse School of Medicine (USA), the National
Institute of Malaria Research (India), and the Centers for
Disease Control and Prevention (CDC) in the United
States were followed. The total numbers of subjects
included in this study are summarized in Table 1. The pri-
mary aim was to compare the immunologic profiles
between MM, CMS and CMNS. Healthy controls (HC)
were included as an additional control group to estimate
the steady state levels of various biomarkers in this study.
Thus, the HC numbers were not equal to that of the
malaria groups. Pregnant women and patients with other
manifestation of severe disease such as respiratory distress
without CM and non-CM related coma, were excluded
from the study. Data relating to age, sex, and level of par-
asitaemia as well as complications such as seizure, renal
failure, acute respiratory failure, impaired hepatic func-
tion, haematuria/spontaneous bleeding/DIC, and psychi-
atric disorder, were obtained from medical records. It was
not possible to include data on non malaria deaths (i.e.,
patients dying of severe neurological disease or of other
non-cerebral disease) to relate specificity of mortalities to
malaria alone. However, recent analyses of CSF and serum
in fatal Ghanaian CM cases revealed that the observations
were not part of a generalized fatal cascade in human dis-
ease [22].
Table 1: Clinical characteristics of the study participants
CATEGORY
CHARACTERISTIC HC MM CMS CMNS
Total number of subjects 25 48 48 12
Adults (≥ 18 yr) 20 33 32 7
Children (< 18 yr) 5 15 16 5
No of males 18 28 34 6
No of females 7 20 14 6
Median age (yr) 22 ± 14 19 ± 14 25 ± 19 20 ± 16
Mean Glasgow Coma Score 14 14 6.7 ± 2.3 5.08 ± 2.2
Seizures 0 0 16 8
Geomean parasitaemia (pRBC/mm3) 0 1594 ± 426.6 4166 ± 650.9 1336 ± 386.2
Geomean haemoglobin (g/dL) 10.1 ± 0.40 9.17 ± 0.38 7.94 ± 0.37 6.82 ± 0.73
Tribal population 4 4 12 4
Non-tribal population 21 44 36 8
Renal failure 0 0 7 2
Geomean duration of admission (days) N/A 3.5 6.4 1.8
Clinical study characteristics of the study participants in Jabalpur, India. HC – healthy controls, MM – mild malaria, CMS – cerebral malaria 
survivors, CMNS – cerebral malaria non-survivors. Relevant clinical data and information (such as duration of coma and seizures) were recorded 
for each patient from physician's records. Venous blood samples from children (2 – 5 ml) and adults (10 ml) were collected soon after enrolment 
into the study at the hospital from HC, MM, CMS, and CMNS groups prior to commencement of anti-malarial treatment or transfusions. Plasma 
was separated after centrifugation in Becton-Dickinson cell preparation tubes and aliquoted and frozen at -80°C for long-term storage.Malaria Journal 2008, 7:83 http://www.malariajournal.com/content/7/1/83
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Enrollment criteria
Cerebral malaria
To be considered a case of CM, a patient had to fulfill the
World Health Organization's definition of severe CM
[36], have a Glasgow coma score of ≤8; have a P. falci-
parum parasitaemia, and have no other clinically evident
cause of impaired consciousness [37]. CMS and CMNS
remained as two separate groups. Non survivors (CMNS)
were enrolled if they died within three days of admission.
Mild malaria
Patients who had fever with P. falciparum parasitaemia of
<25,000 parasites/µl of blood (detected microscopically
from blood smears) and no evidence of impaired con-
sciousness, seizures, and no past history of mental illness,
meningitis, or accidental head injury were included.
Healthy control
Relatives of patients (15) in the hospital and members of
the community (10) who did not have malaria or other
febrile illness were included after clinical evaluation.
Relevant clinical data and information (such as duration
of coma and seizures) were recorded for each patient from
physician's records [38]. Venous blood samples from chil-
dren (2–5 ml) and adults (10 ml) were collected soon
after enrolment into the study at the hospital from HC,
MM, CMS, and CMNS groups prior to commencement of
anti-malarial treatment or transfusions. Plasma was sepa-
rated after centrifugation in Becton-Dickinson cell prepa-
ration tubes (catalogue #362753, BD Pharmingen,
Franklin Lakes, NJ, USA), aliquoted and frozen at -80°C
for long-term storage.
Multiplexed microsphere cytokine immunoassay
Plasma (50 µL) from HC, MM, CMS and CMNS were eval-
uated simultaneously for 26 circulating cytokines ((IL-1β,
IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12 (p70),
IL-13, IL-15, IL-17, Eotaxin, FGF basic protein, G-CSF,
GM-CSF, IFN-γ, IP-10, MCP-1 (MCAF), MIP-1α, MIP-1β,
PDGF bb, RANTES, TNF-α, and VEGF)) using a multiplex
bead-based cytokine immunoassay (MMA) coupled with
the Luminex™ system (Austin, TX) and human-specific
bead sets (BioRad, San Diego, CA), according to the man-
ufacturer's instructions. The results were interpolated
from five-parameter-fit standard curves generated using
the relevant recombinant human proteins (BioRad). Sam-
ples were tested at a 1:4 dilution.
Enzyme-linked immunosorbent assay (ELISA)
Four (4) biomarkers, Fas-ligand (Fas-L), soluble Fas
(sFas), soluble TNF receptor 1 (sTNF-R1) and soluble TNF
receptor 2 (sTNFR-2), were measured by standard
cytokine ELISA, using human-specific primary and sec-
ondary antibodies (Biosource, R&D, and BD Pharmingen,
San Diego, CA). Results were interpolated from five-
parameter-fit standard curves generated with appropriate
recombinant human biomarkers (BD Pharmingen). Sam-
ples were tested at a 1:4 dilution.
Statistical analysis
Demographic variables were compared across the four
study groups using analysis of variance (for continuous
variables) and chi-squared testing (for categorical varia-
bles). Non-parametric tests (Mann-Whitney rank sum
tests) were used for individual cytokine analysis between
groups, while multivariate analyses (Least Squares with
Bonferonni correction) determined biomarker signifi-
cance between groups after modeling and controlling for
covariates (age, sex, and parasitaemia). Correlations
between cytokine levels were assessed by Spearman's rank
correlation. Box plots of biomarker concentrations out-
line the 25th and 75th percentiles, with bars representing
the 10th and 90th percentiles. Values outside the 10th and
90th percentiles are plotted as points. Statistical signifi-
cance (*) in CM cases were set at a two-tailed P < 0.05.
Multinomial logistic regression analysis was used to iden-
tify biomarkers independently associated with disease
severity. Odds ratio estimates produced from this analysis
with healthy controls as the reference group were used to
establish the presence of a trend of increasing disease
severity for increasing biomarker levels (risk factors), or
decreasing disease severity for increasing biomarker levels
(protective factors). STATA™ (College Station, TX, USA)
and SAS™ (Cary, NC, USA) were used to calculate statistics
and plot graphs.
Results
Patient characteristics
A total of 133 subjects were included in this study, and
their characteristics are described in Table 1. The main
complications in CM patients but absent in HC and MM
were seizure (CMS 33.3%, CMNS 66.67%), renal failure
(CMS 14.58%, CMNS 16.7%), acute respiratory failure
(CMS 25%, CMNS 50%), impaired hepatic function
(CMS 18.7%, CMNS 8.3%) haematuria/spontaneous
bleeding/DIC (4.51%) and psychiatric disorder (2.25%).
Age, sex, and level of parasitaemia did not affect predic-
tion of the severity of malaria among the MM, CMS and
CMNS groups (Table 1). Anaemia was present in all study
groups, but the haemoglobin levels were significantly
lower in the CMS (p < 0.009) and CMNS (p < 0.003)
patients as compared to HC. Haemoglobin levels were sig-
nificantly different between MM and CMNS (p < 0.043)
but not between MM and CMS groups. CM mortality rate
was 9%, mostly among subjects with multi-organ failure.
Adults had higher mortality rates due to the presence of
multiple complications (RR-1.88, 95% CI 1.01–3.48).Malaria Journal 2008, 7:83 http://www.malariajournal.com/content/7/1/83
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Biomarker levels in patient groups
In a pilot test, ten plasma samples from each of the four
disease groups (HC, MM, CMS, and CMNS) were selected
and assayed for 30 biomarkers. Median biomarker levels
(box plots) of the 30 biomarkers are presented in Figures
1 and 2. Many biomarkers demonstrated marginal
increases, while some decreased, with increasing disease
severity. Pairwise comparisons were used to determine
levels of significance between disease status after control-
ling for age, sex and parasitaemia. Median levels of 11
Log plasma biomarker levels and disease severity Figure 1
Log plasma biomarker levels and disease severity. Log median levels (pg/ml) of twelve (12) biomarkers [sTNF-R1, sTNF-R2 IL-
1ra, sFas, Fas-L, IP-10, MIP-1β, IL-8, IL-10, VEGF, PDGFbb and FGF basic protein]. With the exception of sFas, Fas-L, sTNF-R1, 
and sTNF-R2 that were measured by ELISA, all other biomarkers were quantified via Luminex™ from blood samples collected 
from patients at time of admission. HC – healthy controls, MM – mild malaria, CMS – cerebral malaria survivors, CMNS – cer-
ebral malaria non-survivors. Box plots represent medians and 25th and 75th percentiles. Bars mark the 10th and 90th percentiles, 
and outliers are plotted as points. HC versus MM, CMS, and CMNS: *** p < 0.05, $$$ p < 0.0045 bonferroni adjustment (alpha 
= 0.05/12)Malaria Journal 2008, 7:83 http://www.malariajournal.com/content/7/1/83
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Log plasma biomarker levels and disease severity Figure 2
Log plasma biomarker levels and disease severity. Log median levels (pg/ml) of eighteen (18) biomarkers [IFN-γ, TNF-α, MIP-
1α, IL-1β, IL-2, RANTES, IL-4, IL-5, G-CSF, IL-6, IL-9, Eotaxin, IL-12 (p70), IL-13, GM-CSF, IL-15, IL-17 and MCP-1 (MCAF)]. 
Biomarkers were quantified via Luminex™ from blood samples collected from patients at time of admission. HC – healthy con-
trols, MM – mild malaria, CMS – cerebral malaria survivors, CMNS – cerebral malaria non-survivors. Box plots represent medi-
ans and 25th and 75th percentiles. Bars mark the 10th and 90th percentiles, and outliers are plotted as points. HC versus MM, 
CMS, and CMNS: *** p < 0.05, $$$ p < 0.0045 bonferroni adjustment (alpha = 0.05/18)Malaria Journal 2008, 7:83 http://www.malariajournal.com/content/7/1/83
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biomarkers (IL-1ra, IL-8, IL-10, sTNF-R1, sTNF-R2, VEGF,
IP-10, MIP-1β, PDGFbb, sFas, and Fas-L) showed signifi-
cant differences between comparison groups. These
biomarkers can be grouped into four major categories:
cytokine receptors (sTNFR1, sTNFR2); cytokines and
chemokine (Il-1ra, IL-8, IL-10, MIP-1β and IP-10); apop-
totic (sFas and Fas-L); and angiogenic factors (VEGF and
PDGFbb).
Having determined that these 11 factors showed impor-
tant trends in different disease categories, the levels of
these factors in all 133 samples (Figure 3) were further
analyzed. The levels of sTNF-R1, sTNF-R2 and IL-1ra in
plasma increased with disease severity (Figures 3a, 3b and
3c). The difference in the mean between CMS and each of
the control groups (HC and MM) were significant for the
three cytokine receptors (except for sTNF-R2 in the CMS
vs. MM group) (Table 2). However, only sTNF-R1 and
sTNF-R2 levels increased in the CMNS group as compared
to CMS group, which was significantly different for sTNF-
R2 (p < 0.05, Table 2). Expression of the apoptotic mark-
ers Fas-L and sFas also increased with disease severity (Fig-
ures 3d and 3e). However, only sFas showed significant
differences across all disease groups, except HC vs. MM
(Table 2). Fas-L levels of the HC were significantly differ-
ent from the other groups (p < 0.05).
Among the chemokines and cytokines evaluated, only IP-
10 levels increased as disease severity increased (Figures 3f
to 3i). The difference in the mean plasma level of IP-10
between HC and MM was not significant, but the differ-
ences between the CMS group and the control groups (HC
and MM) were statistically significant (p < 0.0045 and p <
0.05, respectively, Table 2). Overall, IP-10 levels were
highest in the CMNS group (Figure 3f) and was higher
compared to the MM (p < 0.05), but not the CMS (p >
0.05), group (Table 2). Mean MIP-1β and IL-10 levels
increased significantly in the CMS group in comparison to
the HC group (p < 0.0045), but levels declined in the
CMNS group when compared to CMS (Figures 3g and 3i),
though not statistically significant (Table 2). Mean IL-8
levels were significantly higher in the CMS group com-
pared to the HC and MM control groups, but not in the
CMNS compared to the other groups (Figure 3h, Table 2).
In contrast to the inflammatory cytokines and apoptotic
markers, levels of angiogenic growth factors (VEGF and
PDGFbb) were lowest in severe disease. Among the
selected factors, VEGF levels showed the largest difference
between the CMS and CMNS groups (Figure 3j and Table
2). The decline in VEGF levels in CMNS were highly sig-
nificant compared to the HC, MM and CMS groups (p <
0.0045). Similarly, PDGFbb levels (Figure 3k) were lowest
in CMNS, and significant compared to HC (p < 0.0045).
The differences in PDGFbb levels between CMNS and MM
or CMS were not significant.
Trend analysis using multinomial logistic regression
Since some factors showed important trend towards mor-
tality associated with CM, we did additional analysis
using a multinomial logistic regression to verify the statis-
tical significance of these associations. As shown in Table
3, 10 out of 11 biomarkers are significantly associated
with disease severity. Furthermore, biomarkers IL-1ra, IP-
10, TNF-R1, TNF-R2, Fas-L, and sFas had increasing trend
in odds ratio estimates for disease severity, including
death. This suggests that for these specific biomarkers, as
levels increase, odds of disease severity increase with odds
of mortality being the highest. A protective effect against
mortality was seen for VEGF levels as higher levels of
VEGF decreased the risk of mortality (odds ratio CMNS:
HC = 0.29). PDGFbb did not show any significant trend.
While IL-8, IL-10 and MIP-1b are significantly associated
with disease severity, the odds ratio estimates did not
Table 2: Comparison of predicted means of least squares analyses of biomarkers by disease category
CATEGORY
BIOMARKER OVERALL P-VALUE HC VS. MM HC VS. CMS HC VS. CMNS MM VS. CMS MM VS. CMNS CMS VS. CMNS
IL-1RA 0.0002 p < .05 p < .0045 p < .05 p < .05 NS NS
IL-8 0.0003 p < .05 p < .0045 NS p < .05 NS NS
IL-10 <.0001 p < .0045 p < .0045 NS NS NS NS
STNF-R1 0.0005 NS p < .05 p < .0045 p < .05 p < .05 NS
STNF-R2 0.0002 p < .05 p < .0045 p < .0045 NS p < .05 p < .05
VEGF <.0001 NS NS p < .0045 NS p < .0045 p < .0045
IP-10 0.0005 NS p < .0045 p < .0045 p < .05 p < .05 NS
MIP-1β 0.0001 p < .05 p < .0045 NS NS NS NS
PDGFbb 0.0056 NS p < .05 p < .0045 NS NS NS
SFas < .0001 NS p < .05 p < .0045 p < .05 p < .0045 p < .05
Fas-L 0.0174 p < .05 p < .05 p < .05 NS NS NS
Significant differences in biomarkers in relation to disease severity determined by multivariate analyses (Comparison of Least Squares (Predicted) 
with Bonferonni correction) after modeling and controlling for covariates (age, sex, and parasitaemia).Malaria Journal 2008, 7:83 http://www.malariajournal.com/content/7/1/83
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Biomarkers with significant differences between disease severity groups as determined by multivariate analyses Figure 3
Biomarkers with significant differences between disease severity groups as determined by multivariate analyses. HC – healthy 
controls, MM – mild malaria, CMS – cerebral malaria survivors, CMNS – cerebral malaria non-survivors. Box plots represent 
medians and 25th and 75th percentiles. Bars mark the 10th and 90th percentiles, and outliers are plotted as points. MM versus 
CMS and CMNS: *** p < 0.05, $$$ p < 0.0045 bonferroni adjustment (alpha = 0.05/11), CMS versus CMNS: +++ p < 0.05, ### 
p < 0.0045 bonferroni adjustment (alpha = 0.05/11).Malaria Journal 2008, 7:83 http://www.malariajournal.com/content/7/1/83
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show a strict increasing trend as odds of CM to HC were
higher than odds of CMNS to HC for increasing biomar-
ker levels.
Biomarker ratios and prognostic significance
The ratios of inflammatory markers to apoptotic and ang-
iogenic factors were evaluated to determine differences
between disease groups. Although the median IL-10:TNF-
α ratio was lower in the CMS and CMNS groups as com-
pared to the MM group, there were no significant differ-
ences in the mean ratio between the different groups
(Table 4 and 5). However, both the mean and median of
ratios of IP-10/VEGF, sTNF-R2/VEGF, and sFAS/VEGF
increased as the disease severity increased, with the high-
est ratios in the CMNS group (Table 4). IP-10/PDGFbb,
sTNF-R2/PDGFbb, and sFAS/PDGFbb ratios also
increased with severity, but these ratios were about 10-
fold less when compared to ratios with VEGF (Table 4).
This difference is evident from the correlation coefficients
shown in Figure 4. Most notably, the increase in these
ratios between the CMNS group and other groups, includ-
ing CMS, were highly significant (p < 0.0001, Table 5).
Discussion
Cerebral malaria is a major life-threatening complication
of Plasmodium falciparum infection in humans. However,
the mechanisms underlying fatal cerebral complications
are still not fully understood. The present study was con-
ducted to determine immunologically-relevant biological
factors known to be associated with fatal CM and other
severe forms of malaria in India. We examined disease
associated inflammatory mediators, including cytokines,
chemokines, apoptotic and angiogenic factors in sera of
patients with HC, MM, CMS and CMNS. Due to the lack
of concurrent studies of inflammatory, apoptotic and ang-
iogenic biomarkers in appropriate time-matched controls
Table 3: Analysis of biomarkers for disease severity using multinomial logistic regression
BIOMARKER COMPARISON OF 
DIFFERENT GROUPS
ODDS RATIO ESTIMATE LOWER CONFIDENCE 
LIMIT
UPPER CONFIDENCE 
LIMIT
P-VALUE
log IL-1ra CMNS:HC 4.159 2.257 7.666 <0.0001
CM:HC 3.615 2.177 6.002
MM:HC 2.815 1.74 4.551
log IL-8 CMNS:HC 1.596 0.922 2.762 0.0006
CM:HC 2.542 1.636 3.952
MM:HC 1.815 1.214 2.712
log IL-10 CMNS:HC 3.749 1.915 7.34 <0.0001
CM:HC 4.38 2.364 8.115
MM:HC 4.21 2.278 7.777
log TNF-R1 CMNS:HC 2.23 1.342 3.706 <0.0001
CM:HC 1.541 1.259 1.887
MM:HC 1.406 1.176 1.682
log TNF-R2 CMNS:HC 1.966 1.183 3.265 0.0003
CM:HC 1.279 1.095 1.495
MM:HC 1.387 1.162 1.656
log VEGF CMNS:HC 0.299 0.149 0.6 <0.0001
CM:HC 1.078 0.647 1.794
MM:HC 1.684 0.96 2.953
log IP-10 CMNS:HC 2.724 1.71 4.337 <0.0001
CM:HC 1.889 1.401 2.547
MM:HC 1.391 1.061 1.823
log MIP-1β CMNS:HC 2.901 1.419 5.932 0.0005
CM:HC 3.78 2.038 7.013
MM:HC 3.244 1.763 5.968
log PDGFbb CMNS:HC 0.76 0.555 1.042 0.1863
CM:HC 0.799 0.618 1.035
MM:HC 0.755 0.584 0.975
log sFas CMNS:HC 6.033 2.077 17.523 0.0021
CM:HC 2.515 1.246 5.078
MM:HC 1.244 0.655 2.363
log FasL CMNS:HC 6.914 2.678 17.848 0.0001
CM:HC 1.883 1.261 2.812
MM:HC 1.964 1.303 2.959
HC (healthy control) was used as reference group. This analysis indicates the odds of risk (as indicated for each disease category compared to HC) 
for every one unit increase in log biomarker values. The p values represent the overall group differences. OR: odds ratio.Malaria Journal 2008, 7:83 http://www.malariajournal.com/content/7/1/83
Page 10 of 15
(page number not for citation purposes)
from other diseases, the results are discussed in context.
The study was conducted in an area of P. falciparum trans-
mission where life-threatening complications of malaria
occur.
The involvement of sTNF-R, sFas and IL-10 in the patho-
genesis of CM and its associated mortality is consistent
with previous reports. Mice deficient in TNF-R2 (TNF-R2-
/-) or Fas ligand (Fas-/-) survive longer than wild type
mice in experimental studies of CM, while TNF-R2-/- mice
survive the longest in the absence of anti-malarial treat-
ment [39]. The critical role of TNF-R2 in CM-associated
death in experimental malaria has been well established
[39-41]. In the absence of TNF-R2, mortality was elimi-
nated in mice [39], while the restoration of TNF-R2
expression in brain tissue induced lethal CM [41]. Ele-
vated levels of sTNF-R1 and sTNF-R2 in African children
afflicted with CM have been reported, but no significant
correlation with CM-associated mortality has been dem-
onstrated [40,42]. This study has shown that plasma lev-
els of sTNF-R2 are significantly higher in CMNS than in
other groups. Since epidemiological and phenotypic dif-
ferences exist between Indian and West African CM, fur-
ther studies on the validity of these findings in South
American, and other Asian settings may clarify these dif-
ferences.
sFas and its ligand, Fas-L, are critical factors mediating
malaria pathogenesis in both murine CM models and in
human CM. Fas-deficient mice are protected against CM,
while Fas and Fas-L expression increased in brain tissue of
wild type mice with CM [43]. Fas and Fas-L interactions
activate the classical extrinsic apoptotic pathway involv-
ing caspase cascades (caspase-8, -9, and -3) and activated
caspase-3-positive apoptotic astrocytes have been found
in mice affected by CM [8]. In a recent study in Gabon,
Touré et al [44] demonstrated that although the factors
inducing apoptosis have not been identified, apoptosis
may play an important role in triggering some of the neu-
rological manifestation associated with severe malaria.
The present study has confirmed a robust positive correla-
tion between sFas levels and CM fatality as was observed
in postmortem CSF and serum in Ghanaian CM patients
[22]. Thus, efforts are underway to test postmortem tis-
sues and CSF from this Indian population in future inves-
tigations relating to CM mediated apoptosis and severity.
Mean IL-10 levels increased in the CMS group in compar-
ison to the HC group but the levels declined in the CMNS
Table 4: Ratios of anti-inflammatory, angiostatic and apoptotic 
factors versus pro-inflammatory and angiogenic factors and 
relation to disease severity
CATEGORY
BIOMARKER RATIOS HC MM CMS CMNS
IL10:TNFα
Mean 0.43 12.97 16.97 159.56
SEM 0.11 5.29 13.9 155.84
IP10:VEGF
Mean 1.47 7.54 45.24 548.58
SEM 0.42 2.79 17.66 258.12
IP10:PDGFbb
Mean 0.28 1.49 10.03 54.8
SEM 0.15 0.43 3.97 29.6
sTNFR2:VEGF
Mean 34.7 469 1262 12945
SEM 17.98 168.2 461.45 4188
sTNFR2:PDGFbb
Mean 11 160 286 1416
SEM 4.45 50.93 93.39 568
sFas:VEGF
Mean 74 53.3 167 2090
SEM 16.37 9.3 47.07 813
sFas:PDGFbb
Mean 8.78 23.6 50.8 212
SEM 1.75 5.21 17.59 88
The ratios of anti-inflammatory, angiostatic and apoptotic factors 
versus pro-inflammatory and angiogenic factors in different subject 
groups. SEM = standard error of the mean
Table 5: Predicted mean ratios of ANOVA analyses of CM prognostic biomarkers
CATEGORY
BIOMARKER RATIO OVERALL P-VALUE HC vs. MM HC vs. CMS HC vs. CMNS MM vs. CMS MM vs. CMNS CMS vs. CMNS
IL10:TNFa 0.3096
IP10:VEGF <0.0001 NS NS <0.0001 NS <0.0001 <0.0001
IP10:PDGFbb 0.0001 NS NS <0.0001 NS <0.0001 0.001
STNFR2:VEGF <0.0001 NS NS <0.0001 NS <0.0001 <0.0001
STNFR2:PDGFbb <0.0001 NS NS <0.0001 NS <0.0001 <0.0001
sFas:VEGF <0.0001 NS NS <0.0001 NS <0.0001 <0.0001
sFas:PDGFbb <0.0001 NS NS <0.0001 NS <0.0001 <0.0001
Statistical comparison of predicted mean ratios of anti-inflammatory, angiostatic and apoptotic factors versus pro-inflammatory and angiogenic 
factors in different subject groups. P < 0.05 considered statistically significant; NS, not statistically significant.Malaria Journal 2008, 7:83 http://www.malariajournal.com/content/7/1/83
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group when compared to CMS. Interestingly, this decline
coincided with a significant increase in IP-10 production
as previously reported [22]. Interleukin-10 (IL-10) is a
pleiotropic cytokine that inhibits the production of inter-
feron-gamma (IFN-γ) by T helper 1 (Thl) cells and TNF
secretion by macrophages. The protective role of IL-10 in
CM severity has previously been demonstrated in murine
CM models. In vivo neutralization of endogenous IL-10
in CM-resistant mice resulted in CM while increased pro-
duction of IL-10 inhibited P. berghei ANKA antigen-spe-
cific IFN-γ and protected against CM in susceptible mice
[45]. Recent studies have shown elevated levels of circulat-
ing IL-10 in patients with cerebral and severe malaria but
less so in mild malaria. Thus, it seems that the decreased
production of IL-10 in non survivors (CMNS) probably
enhances production of IFN-γ and IP-10; an interferon
inducible protein, to increase CM severity. Further mech-
anistic study is needed to determine the role of IL-10 in
fatal outcomes of CM.
The study also revealed that VEGF may play a protective
role against mortality associated with CM. VEGF is a vas-
cular permeability factor with potent angiogenic and
wound healing properties [46]. VEGF also interacts with
PDGFbb and other factors such as thrombospondin-1
(TSP-1) and transforming growth factor beta (TGF-β)
[47]. There is substantial evidence demonstrating the
importance of VEGF in brain tissue repair and in CNS
Relationship of the mean ratios of IP-10, sTNF-R2, and sFas to angiogenic protective factors VEGF and PDGF bb with disease  severity Figure 4
Relationship of the mean ratios of IP-10, sTNF-R2, and sFas to angiogenic protective factors VEGF and PDGF bb with disease 
severity. Line represents best fit with 95% confidence intervals in shaded regions.Malaria Journal 2008, 7:83 http://www.malariajournal.com/content/7/1/83
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wound healing [48,49]. Exogenous administration of
VEGF to injured brain tissues improved wound repair,
functional response and decreased apoptosis in rats [50].
Decreased levels of serum VEGF and PDGFbb correlated
with fatal outcome in CM. Interestingly, a decrease in lev-
els of PDGFbb has been reported in CSF and serum of non
survivors of CM [22]. Whether the decline in levels of
VEGF or PDGFbb are causative agents of CM mortality or
a specific phenotype of patients with susceptibility to fatal
CM needs further evaluation. Based on this observation, it
seems that significant decreases in VEGF may exacerbate
neurological damage triggered by inflammatory- and/or
parasite-derived factors, thus leading to death. It has been
shown that neutralization of endogenous VEGF in the
brains of injured rats results in decreased angiogenic activ-
ity and increased vascular and astrocyte degeneration,
leading to larger wound cavities [48]. It is unclear why or
how VEGF and PDGFbb production declines in the
peripheral blood of CM patients. VEGF expression is neg-
ligible in the CNS under normal conditions, and it is acti-
vated after various types of neurological injuries [49]. In
addition, elevated levels of VEGF-positive astrocytes and
deposition of VEGF receptor-1 (VEGFR-1 or Flt-1) in
Durck's granulomas were found in non-surviving CM
patients [4]. Recently, elevated levels of VEGF in P. falci-
parum-infected primigravid mothers were reported [50].
Thus, it is evident that VEGF is involved in severe manifes-
tations of malaria, although further studies will be
required to fully understand its role in fatal outcomes of
severe malaria. In a recent study involving Kenyan chil-
dren, it was demonstrated that erythropoietin but not
VEGF was associated with neurological sequelae [51]. It
remains to be determined whether the differences
between our study findings and the Kenyan study is due
to differences in malaria epidemiology, immune status of
the patients or host population genetics.
IP-10 (CXCL10) is a chemokine that is induced by IFN-γ,
TNF-α, and other factors and has chemotactic activity for
activated Th1 lymphocytes. There is growing evidence
implicating this chemokine in both infectious and nonin-
fectious causes of neuronal injury, dementia and inhibi-
tion of angiogenesis [52-54]. In this study, IP-10 levels
were remarkably elevated as disease severity increases,
with highest levels among non-survivors of CM (CMNS).
These findings are consistent with recent studies on sera
obtained from CM non-survivors in Ghana [22] as well as
other reports implicating inflammatory and apoptotic
mechanisms in the pathogenesis of CM [8-12].
This study confirmed an observed link between elevated
levels of transcripts of genes implicating interferon-regu-
lated processes and apoptosis in a murine CM model [55]
and of elevated IP-10 in CM patients with poor prognosis
[22]. It seems that TNF-α which is activated following the
release of malaria antigens after schizont rupture, may
activate production of IP-10 in brain capillaries and astro-
cytes [56,57]. IP-10 in concert with TNF-α can cause vas-
cular injury resulting in breakdown in the blood brain
barrier, which leads to accumulation of leukocytes that
induce local hyper-inflammation. Significant down regu-
lation of VEGF may further inhibit angiogenesis and
regeneration of damaged blood capillaries. High systemic
levels of IP-10, with its strong angiostatic properties, in
CM patients may further inhibit angiogenesis and inter-
fere with VEGF function. IP-10 also blocks VEGF interac-
tion with its natural ligand by interacting with cell-surface
glycosaminoglycans which provide accessory support for
VEGF [58]. In viral meningitis, high levels of IP-10 in the
cerebrospinal fluid (CSF) have been reported [54]. High
levels of IP-10 have also been found in the CSF of patients
with HIV-associated dementia correlated with neuropsy-
chiatric impairment [59]. Furthermore, mouse studies
have demonstrated that the HIV-1 virus-encoded protein
gp120 directly activates astrocytes to produce IP-10 using
a novel mechanism independent of IFN-α and the STAT-1
pathway of IP-10 induction [52]. In addition, elevated lev-
els of IP-10, especially from astrcoytes, have been detected
in Japanese encephalitis patients [60]. Based on these
findings and those from other infectious disease models,
it appears that IP-10 may play a more important role in
CM-related brain encephalopathy/injury than previously
thought. A very recent experimental CM study using
knockout mice which lacked either IP-10, Mig or their
receptor CXCR3, demonstrated that these molecules
played a critical role in the CM associated death caused by
P. berghei ANKA infection. It was further shown that IP-10
and Mig play a role in attracting CD8+T cells and NK cells
to brains of infected mice and may be involved in causing
death. In the infected mice, brain endothelial cells lining
blood capillaries expressed both IP-10 and Mig while the
neurons expressed IP-10 [61]. Collectively, these evi-
dences suggest a prominent role for IP-10 in the patho-
genesis of CM and associated death.
The inverse relationship between inflammatory factors
and apoptotic and angiogenic markers were striking. In
previous studies, the IL-10 (anti-inflammatory) to TNF-α
(pro-inflammatory) ratio had been shown to be lower in
severe malaria anaemia than in controls [62]. Interest-
ingly, in this study sTNF-R2/VEGF, IP-10/VEGF and sFas/
VEGF ratios were highest in the CMNS group; and were at
least 10-fold higher as compared to the CMS group. This
difference supports the hypothesis that the relative bal-
ance in inflammatory markers and apoptotic or ang-
iogenic factors, especially VEGF, may predict risk of CM-
associated mortality. These ratios could be used as prog-
nostic markers in predicting fatal or severe outcomes asso-
ciated with CM.Malaria Journal 2008, 7:83 http://www.malariajournal.com/content/7/1/83
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Conclusion
This study has demonstrated that IP-10, sTNF-R2 and sFas
(inflammation and apoptotic factors) are positively (risk
factors for disease) correlated, while VEGF, an angiogenic
and anti-apoptotic factor is negatively (protective) corre-
lated with mortality associated with CM. The findings
have provided new insights on the contribution of patho-
gen induced host factors to severity of CM and confirm
recent findings that inflammatory chemokines such as IP-
10 and factors involved in the extrinsic apoptotic pathway
play a critical role in the pathogenesis of fatal CM. An
important observation is the potential protective role of
VEGF against fatal CM which may be worth investigating
for development of strategies to improve treatment out-
comes in CM patients. In addition, it has been demon-
strated that the ratios of VEGF to IP-10, sTNF-R2, and sFas
may indeed be used in predicting risk of developing fatal
CM. Further analysis of these factors in patients dying of
non CM-related causes and in CM patients from other
geographic regions, will greatly improve current under-
standing of the pathogenic mechanisms involved in CM
and enhance development of new prognostic markers and
adjunctive therapies for improvement of treatment out-
comes of CM.
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